Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRILOGY long-term extension study of guselkumab in pediatric Crohn's disease, ulcerative colitis, and juvenile psoriatic arthritis
MOH_2026-07-09_016927Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of guselkumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on MOH_2026-07-09_016927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-09_016927.